Related references
Note: Only part of the references are listed.Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
Chang Gon Kim et al.
JOURNAL OF HEPATOLOGY (2021)
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice
Jordi Rimola et al.
EUROPEAN JOURNAL OF RADIOLOGY (2021)
Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot
Jordi Bruix
JOURNAL OF HEPATOLOGY (2021)
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
Zhenggang Ren et al.
LANCET ONCOLOGY (2021)
Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease
Melissa Palmer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
When Can Intermediate Outcomes Be Used as Surrogate Outcomes?
David L. DeMets et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Thomas Yau et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2020)
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Robin K. Kelley et al.
ADVANCES IN THERAPY (2020)
The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT
Manuel de la Torre-Alaez et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2020)
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
Angel Alsina et al.
LIVER CANCER (2020)
Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
Arndt Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review
Elodie Klajer et al.
SEMINARS IN ONCOLOGY (2020)
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis
Alvaro Diaz-Gonzalez et al.
LIVER INTERNATIONAL (2020)
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
Charles Dolladille et al.
JAMA ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Robin Kate Kelley et al.
CLINICAL CANCER RESEARCH (2020)
A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
Katy Cooper et al.
BRITISH JOURNAL OF CANCER (2020)
Treatment-related toxicity predicts for improved outcome in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitor therapy
David J. Pinato et al.
JOURNAL OF HEPATOLOGY (2020)
Treatment after progression in the era of immunotherapy
Salem Billan et al.
LANCET ONCOLOGY (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
Robin Kate Kelley et al.
ESMO OPEN (2020)
Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
Masatoshi Kudo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).
Max W. Sung et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre
Friedrich Foerster et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2019)
Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma
Lorenza Rimassa et al.
CANCER TREATMENT REVIEWS (2019)
Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2019)
Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
Bishal Gyawali et al.
JAMA INTERNAL MEDICINE (2019)
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation
Massimo Iavarone et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2019)
Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series
Swetha Kambhampati et al.
CANCER (2019)
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2019)
Insights into the success and failure of systemic therapy for hepatocellular carcinoma
Jordi Bruix et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study
Masatoshi Kudo et al.
CANCERS (2019)
755PAlpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial
J Bruix et al.
ANNALS OF ONCOLOGY (2019)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T Yau et al.
ANNALS OF ONCOLOGY (2019)
Novel patterns of response under immunotherapy
E. Borcoman et al.
ANNALS OF ONCOLOGY (2019)
A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
Alyson Haslam et al.
EUROPEAN JOURNAL OF CANCER (2019)
Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials
Run-Cong Nie et al.
EUROPEAN JOURNAL OF CANCER (2019)
Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study
David J. Pinato et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease A Systematic Review
Noha Abdel-Wahab et al.
ANNALS OF INTERNAL MEDICINE (2018)
Clinical states of cirrhosis and competing risks
Gennaro D'Amico et al.
JOURNAL OF HEPATOLOGY (2018)
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
Richard S. Finn et al.
JOURNAL OF HEPATOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Use of checkpoint inhibitors in liver transplant recipients
Stefan Munker et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2018)
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.
Jordi Bruix et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
RECIST-learning from the past to build the future
Saskia Litiere et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2017)
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
Riccardo Lencioni et al.
JOURNAL OF HEPATOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Hepatocellular carcinoma: an evolving challenge in viral hepatitis and HIV coinfection
David J. Pinato et al.
AIDS (2017)
Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension
Roberto de Franchis
JOURNAL OF HEPATOLOGY (2015)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2015)
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2015)
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2014)
Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST
Maria Reig et al.
SEMINARS IN LIVER DISEASE (2014)
Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients
Massimiliano Berretta et al.
ANTI-CANCER DRUGS (2013)
Postprogression Survival of Patients With Advanced Hepatocellular Carcinoma: Rationale for Second-Line Trial Design
Maria Reig et al.
HEPATOLOGY (2013)
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
Nicola Personeni et al.
JOURNAL OF HEPATOLOGY (2012)
When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression
Geoffrey R. Oxnard et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Biomarkers and surrogate end points-the challenge of statistical validation
Marc Buyse et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Evaluation of Tumor Response After Locoregional Therapies in Hepatocellular Carcinoma Are Response Evaluation Criteria in Solid Tumors Reliable?
Alejandro Forner et al.
CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis
Marcus Alexander Wörns et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2009)
Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
Antonius A. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
Youjin Je et al.
LANCET ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis
Matthias Pinter et al.
ONCOLOGIST (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference
J Bruix et al.
JOURNAL OF HEPATOLOGY (2001)
Share Paper
